Idioma:

[omega]-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential

Schroeder, Christina I ; Lewis, Richard J

Marine Drugs, 2006, Vol.4 (3), p.193 [Periódico revisado por pares]

Texto completo disponível

Citações Citado por

Título:
[omega]-Conotoxins GVIA, MVIIA and CVID: SAR and Clinical Potential
Autor: Schroeder, Christina I ; Lewis, Richard J
É parte de: Marine Drugs, 2006, Vol.4 (3), p.193
Descrição: Highly selective N-type voltage-gated calcium (CaV) channel inhibitors from cone snail venom (the ω-conotoxins) have emerged as a new class of therapeutics for the treatment of chronic and neuropathic pain. Earlier in 2005, Prialt (Elan) or synthetic ω-conotoxin MVIIA, was the first ω-conotoxin to be approved by Food and Drug Administration for human use. This review compares the action of three ω-conotoxins, GVIA, MVIIA and CVID, describing their structure-activity relationships and potential as leads for the design of improved N-type therapeutics that are more useful in the treatment of chronic pain.
Editor: Basel: MDPI AG
Idioma: Inglês

Voltar para lista de resultados